Agios Pharmaceuticals reported Q3 2026 financial results, highlighted by record quarterly net product revenue of $55.4 million, a four-fold increase year-over-year driven by the U.S. launch of AQVESME in thalassemia. The company ended the quarter with $907 million in cash and is preparing for a potential February 2027 FDA approval of mitapivat in sickle cell disease.
Term
Q3 2026
“The third quarter was a record for our product revenue, outperforming our entire 2025 total in just three months. This growth was driven by the U.S. commercial launch of AQVESME in thalassemia, where broadening demand is translating into a durable base of patients on therapy.”
Brian Goff, Chief Executive Officer
“This launch has built the commercial foundation for our largest indication opportunity with mitapivat – sickle cell disease. Our conviction in mitapivat for patients with sickle cell disease is grounded in the robust efficacy and safety data generated to date and we are launch-ready ahead of our PDUFA goal date of February 1, 2027.”
United Parks & Resorts reported third quarter 2026 results with total revenue of $506.5 million and net income of $80.0 million, both down slightly year-over-year due to unfavorable weather and international headwinds. Despite a 4.7% decline in attendance, the company achieved record in-park per capita spending of $37.39 and reported an 8% increase in total pass sales.
Term
Q3 2026
“We are pleased with the underlying performance of our business, despite significantly unfavorable weather, calendar impacts and international headwinds during the quarter. Excluding the impact of these unusual headwinds, which amounted to approximately 325,000 visits, our attendance would have been up.”
Marc Swanson, CEO of United Parks & Resorts Inc.
“Looking ahead to 2027 and beyond, we see a clear path to deliver significantly higher attendance, revenue, Adjusted EBITDA and free cash flow.”
NCR Voyix reported third quarter 2026 financial results with revenue of $539 million, reflecting the impact of its hardware business transition. The company reported net income from continuing operations of $14 million and maintained its full-year 2026 outlook, though it now expects revenue to be at the lower end of its previously stated range.
“Our third quarter results were in line with our expectations, with our strong customer signings reflecting increasing demand for our Voyix Commerce Platform applications. The growth in remaining contract value, coupled with the progress we have made in scaling our deployments, reinforces our confidence in the opportunity ahead.”
James G. Kelly, Chief Executive Officer of NCR Voyix
Perimeter Group reported Q3 2026 financial results with net sales increasing 24% to $389.9 million and net income of $304.5 million. The company also completed its corporate name change from Perimeter Solutions, Inc. and integrated the $117.1 million acquisition of Monaco Enterprises.
InfuSystem Holdings reported Q3 2026 net revenues of $37.6 million, a 3% increase year-over-year, driven by strong growth in Oncology and Wound Care. Net income rose to $3.2 million, or $0.15 per diluted share, while Adjusted EBITDA margin expanded to 24.9%. The company reaffirmed its full-year 2026 guidance, expecting pro-forma revenue growth of 6% to 8%.
Term
Q3 2026
“We delivered another strong quarter, achieving record revenue of $37.6 million. After adjusting for the impact of the previously announced GE Healthcare contract restructuring, pro-forma revenue increased 10.2% compared to the prior-year period. Pro-forma growth has accelerated each quarter this year, up from 1.7% in the first quarter and 7.5% in the second quarter. We also increased Adjusted EBITDA by 12.5% and expanded Adjusted EBITDA margin to 24.9% from 22.8% in the prior-year period. These results reflect continued execution of our profitable growth strategy across our diversified operating platform.”
Carrie Lachance, Chief Executive Officer
“Growth during the quarter was driven by Oncology, where revenue grew 7.2%, and exceptional performance in Wound Care. Wound Care revenue increased $2.0 million, or 112%, compared to the prior-year period, including approximately $1.6 million of growth from our compression therapy product lines focused on lymphedema treatment.”
Becton, Dickinson and Company (BD) reported Q4 fiscal 2026 revenue of $5.3 billion, a 5.4% increase, and full-year revenue of $19.5 billion. The company highlighted the completion of its transformation into a more focused MedTech company following the separation of its Life Sciences business and issued guidance for fiscal 2027.
“We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms. Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company with separation of our Life Sciences business. We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation and drive greater productivity. We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD.”
Advance Auto Parts reported Q3 2026 net sales of $2.01 billion, a 1.2% decrease in comparable store sales. Despite a volatile demand environment, the company delivered an adjusted operating margin of 4.5% and raised its full-year free cash flow guidance to approximately $150 million.
Term
Q3 2026
“Our comparable sales performance improved as the quarter progressed. Main Street Pro outperformed throughout the quarter while DIY trends improved compared to the softer trends experienced during the summer. I thank the team for their hard work and commitment to serving our customers.”
Shane O'Kelly, president and chief executive officer
“Sales declined in the low-single-digit range during the first eight weeks before turning positive in the final four weeks, supported by improved transaction volumes. The Pro channel led performance in Q3, with low-single-digit sales growth including stronger Main Street Pro growth.”
Shane O'Kelly, president and chief executive officer
LeMaitre Vascular reported net sales of $68.0 million for Q3 2026, a 11% increase over the prior year, though net income decreased to $15.0 million from $17.4 million. For the nine months ended September 30, 2026, the company saw improved profitability with net income rising to $47.8 million compared to $42.2 million in the same period of 2025.
Graham Corp reported second quarter fiscal 2027 results with net sales increasing 6% to $69.8 million and net income rising 50% to $4.6 million. The company achieved a record backlog of $561.3 million and reaffirmed its full-year fiscal 2027 guidance for sales and adjusted EBITDA.
Term
Q2 2027
“Our second quarter results reflect strong execution across the business, highlighted by growth in Defense and Space, significant margin expansion and continued momentum across our end markets. Our record backlog of $561 million provides strong visibility into future growth and reinforces our confidence in the long-term opportunities ahead.”
Matthew J. Malone, President and Chief Executive Officer
“We are very pleased with the progress of FlackTek’s integration and the continued execution of our strategic initiatives, including the successful completion of our first customer test at our new cryogenic testing facility and the groundbreaking of our new facility in Arvada.”
Matthew J. Malone, President and Chief Executive Officer
Aspen Aerogels reported Q3 2026 revenue of $85.2 million, a 71% increase quarter-over-quarter, driven by growth in both Thermal Barrier and Energy Industrial segments. The company reported a net loss of $10.4 million, which included $15.1 million in costs related to an incident at its East Providence facility, while Adjusted EBITDA reached $19.8 million. Additionally, the company appointed Stacy D. Nieuwoudt to its Board of Directors, increasing the board size to seven members.
The GEO Group reported record-breaking third quarter 2026 results with revenues increasing 12% to $761.1 million and Adjusted EBITDA rising 21% to $145.3 million. The company updated its full-year 2026 guidance, including a significant increase in net income expectations following the $950 million sale of its Adelanto, California ICE Complex.
“Our diversified business units have continued to deliver strong financial and operational performance throughout 2026, and our third quarter 2026 results marked a record-breaking quarter for GEO, with the highest level of quarterly revenues and adjusted EBITDA ever reported in our company’s history.”
George C. Zoley, GEO’s Chairman, Chief Executive Officer and Founder
“Given the intrinsic value of our assets, including 48,000 owned beds; our strong financial performance in providing diversified secure support services; and our expected future growth, we believe that our stock continues to be significantly undervalued and that share repurchases are therefore a paramount capital allocation priority for our Company.”
George C. Zoley, GEO’s Chairman, Chief Executive Officer and Founder
Planet Fitness reported Q3 2026 financial results with total revenue increasing 9% to $360.0 million and system-wide same club sales growth of 1.5%. The company also announced a new $500 million share repurchase authorization and its entry into the Portuguese market through the acquisition of Be-Fit.
Term
Q3 2026
“We delivered same club sales growth ahead of our expectations and adjusted EBITDA margins of approximately 41% while making meaningful progress on the initiatives designed to accelerate member growth, reinforce affordability, and generate long-term value during the third quarter.”
Colleen Keating, Chief Executive Officer
“We are also energized by the international expansion opportunities available to us, most recently our acquisition of Be-Fit in Portugal, which marks our entry into a sixth international market and our second country in Europe.”
For the three months ended September 30, 2026, Regis Corp reported total revenue of $54.3 million, a decrease from $59.0 million in the prior year period. Net income for the quarter was $0.5 million, or $0.21 per basic share, compared to $1.4 million, or $0.56 per basic share, in the same period of 2025.
Regis Corporation reported financial results for its first fiscal quarter of 2027, achieving operating income of $5.3 million and consolidated same-store sales growth of 0.2%. The company generated positive cash from operations for the eighth consecutive quarter and repaid approximately $7.9 million of debt. Management noted that after reviewing refinancing alternatives, they intend to return to the debt markets in early calendar 2027 to take advantage of lower call premiums.
Term
Q1 2027
“In the first fiscal quarter, we achieved operating income of $5.3 million, Adjusted EBITDA of $7.7 million, and generated positive cash from operations, reinforcing a solid foundation for improving performance across our business. Supercuts delivered a 2.0% increase in same-store sales, contributing to modest overall growth across the Regis portfolio. At the same time, declining guest traffic in our company-owned salons requires immediate attention. We are taking targeted actions to increase traffic across our brands and build a stronger business that delivers sustainable growth and long-term value for our shareholders.”
Susan Lintonsmith, Regis Corporation’s President and Chief Executive Officer
“During the first quarter, we repaid approximately $7.9 million of debt and ended the quarter with $20.8 million in cash. We recently completed a comprehensive review of refinancing alternatives with active oversight from our Board, and working closely with our newest director, who is a significant shareholder. We evaluated a range of options including senior bank debt, private credit financing, preferred equity structures, and whole business securitization. Based on the feedback we received, we determined that refinancing now would not deliver sufficient value to shareholders, given the scheduled decline in the call premium on our existing debt in mid-2027.”
Kersten Zupfer, Regis Corporation’s Executive Vice President and Chief Financial Officer
FS KKR Capital Corp reported a net decrease in net assets resulting from operations of $404 million for the nine months ended September 30, 2026, compared to a $125 million increase in the prior year period. The company's net asset value per share declined to $18.28 from $20.89 at the end of 2025, primarily driven by net realized and unrealized losses on investments.
Enovis Corporation reported net sales of $558.7 million for the third quarter of 2026, a slight increase from $548.9 million in the prior year. The company achieved a net income of $3.4 million for the quarter, a significant recovery from a net loss of $570.9 million in Q3 2025, which was primarily driven by a $548.4 million goodwill impairment charge.
NexPoint Real Estate Finance reported Q3 2026 financial results with a net loss of $12.2 million and cash available for distribution of $14.0 million. The company maintained a $1.0 billion investment portfolio focused on life sciences and multifamily sectors and provided Q4 2026 earnings guidance.
Term
Q3 2026
“Our third quarter results reflect the consistency of the strategy we’ve outlined for investors: earnings that covered our dividend and a portfolio focused on sectors with durable demand. While many lenders continue to work through legacy credit issues, our disciplined underwriting allows us to stay selective and deploy capital where we see the best risk-adjusted opportunities, supporting stable income, portfolio growth, and long-term value for our shareholders.”
Trulieve reported a net loss of $403.0 million for the nine months ended September 30, 2026, primarily driven by a $403.3 million loss on a Deconsolidation Transaction. Revenue for the nine-month period decreased to $787.9 million from $888.0 million in the prior year, while cash and cash equivalents increased to $326.7 million.
Air Products reported fiscal year 2026 results with sales of $13.0 billion, an 8% increase over the prior year, and adjusted EPS of $13.45, up 12%. The company provided fiscal 2027 adjusted EPS guidance of $14.15 to $14.50 and expects capital expenditures between $3.0 billion and $3.5 billion.
The Cigna Group reported third quarter 2026 total revenues of $73.7 billion, a 6% increase year-over-year, driven by growth in Evernorth Health Services and Cigna Healthcare. The company raised its full-year 2026 outlook for adjusted income from operations to at least $30.60 per share and announced a multi-year $3 billion modernization initiative called 'Accelerate to One'.
Term
3 months
“Our vision for The Cigna Group’s next chapter of profitable growth is grounded in delivering greater value and personalized experiences for our customers, with three priorities: driving core growth, leveraging our distinct capabilities, and executing with discipline. As we put our strategy in action, our strong third quarter results demonstrate how we are building on this momentum by making health care more affordable and personalized, while advancing Accelerate to One to drive productivity, reduce costs, and support sustained long-term earnings growth.”
Brian Evanko, President and Chief Executive Officer of The Cigna Group
Trulieve Cannabis Corp. reported Q3 2026 revenue of $230 million and positive net income of $1 million, marking a significant period following its uplisting to the NYSE. The company highlighted major regulatory milestones, including receiving final DEA registrations for medical marijuana dispensaries and the removal of 280E tax burdens.
“State licensed medical marijuana rescheduling unlocked major milestones including DEA registration, removal of 280E tax, and uplisting to the NYSE. Third quarter results demonstrate the strength of our medical cannabis platform underscored by revenue, margins, and cash generation. With meaningful growth expansion opportunities in Georgia and Texas, we are in the early stages of an accelerated growth cycle.”
Walker & Dunlop reported a net loss of $37.3 million for the third quarter of 2026, a significant decline from a $33.5 million profit in the prior year, primarily driven by a surge in indemnified and repurchased loan expenses. Total revenues decreased by 11.6% to $298.4 million for the quarter, while total assets fell to $4.26 billion as of September 30, 2026.
Cognition Therapeutics reported a decrease in cash and cash equivalents to $30.8 million as of September 30, 2026, compared to $36.8 million at year-end 2025. The company's accumulated deficit grew to $211.3 million, reflecting ongoing clinical development costs for its lead product candidate, zervimesine (CT1812).
Targa Resources reported Q3 2026 net income of $658 million and record adjusted EBITDA of $1.5 billion, driven by record Permian inlet and NGL fractionation volumes. The company raised its full-year 2026 adjusted EBITDA guidance to at least $6.0 billion and announced plans for a 20% dividend increase in 2027.
Ducommun Incorporated reported a restatement of prior consolidated financial statements and identified a material weakness in internal control over financial reporting. The company's balance sheet as of October 3, 2026, shows $39.2 million in cash and $163.2 million in net accounts receivable, with total shares outstanding of 15,124,087 as of October 29, 2026.
Ingredion reported third quarter 2026 results with reported diluted EPS of $2.23 and adjusted diluted EPS of $2.28, both down from the prior year. The company lowered its full-year 2026 guidance, citing a slower-than-anticipated recovery at its Argo facility and pressure from higher input costs and soft consumer demand.
Term
Q3 2026
“Our third quarter results fell short of our expectations, largely due to Argo’s slower than anticipated financial recovery, with incremental pressure from higher input costs and consumer softness.”
Jim Zallie, chairman, president and CEO
“As a result, we are lowering our full-year outlook, primarily to reflect the slower earnings recovery in Food & Industrial Ingredients—U.S./CAN, along with the impacts of higher input costs and softer demand.”
Ducommun Incorporated reported record third-quarter 2026 revenue of $227.0 million and an all-time high gross margin of 28.9%. The company achieved a record backlog (RPO) of $1.3 billion, driven by strong commercial aerospace growth and a defense book-to-bill ratio of 2.2x.
Term
Q3 2026
“Another excellent quarter for Ducommun in 2026. With record revenue and gross margins in Q3, we continued to make great progress towards accomplishing our VISION 2027 goals and positioning ourselves for our new VISION 2032 Plan which was communicated in September.”
Stephen G. Oswald, chairman, president and chief executive officer
“Gross margin expansion is an important story for DCO and its investors and was once again very strong in the quarter expanding 140 bps year-over-year to another all-time record of 28.9%.”
Stephen G. Oswald, chairman, president and chief executive officer
Enovis reported Q3 2026 net sales of $559 million, representing 5% organic growth, driven by a 6% increase in its Reconstructive segment. The company raised its full-year 2026 guidance for adjusted EBITDA and adjusted EPS while announcing a new $200 million share repurchase authorization.
Term
Q3 2026
“Our third-quarter results reflect continued progress against our innovation-led strategy and the benefits of executing with greater alignment, accountability, and discipline.”
Damien McDonald, Chief Executive Officer of Enovis
“Growth was consistent with our expectations for the quarter, with continued share gains in Recon and steady performance in Prevention & Recovery.”
Damien McDonald, Chief Executive Officer of Enovis
Privia Health Group reported strong third quarter 2026 results with revenue increasing 13.2% year-over-year to $657.0 million and net income nearly doubling to $13.5 million. The company raised its full-year 2026 guidance across all key financial metrics and announced the acquisition of American Choice Healthcare's MSSP business to expand its value-based care footprint.
Prestige Consumer Healthcare reported total revenues of $336.3 million for the quarter ended September 30, 2026, up from $274.1 million in the prior year, though net income decreased to $25.3 million due to higher interest expenses and acquisition-related costs. The company significantly expanded its balance sheet through a $1.19 billion acquisition, funded by new term loans and senior notes.